ABSTRACT
Valproic acid in 100, 200 and 400 mg/kg doses produced a significant dose dependent decrease in exploratory behaviour, tested as number of head dips on the hole board. In the open field test, control mice entered less number of peripheral squares and more number of central squares on day 4 as compared to day 1 of the test. In the lower doses (100 and 200 mg/kg) valproic acid increased central square entries on day 1 with significant decrease by all doses on subsequent days indicating inhibition of exploratory behaviour. However, in peripheral square entry they followed the same pattern as control mice. Neither carbamazepine (10 and 20 mg/kg) nor ethosuccimide (100 and 200 mg/kg) affected exploratory behaviour in either the hole board or open field test.
Subject(s)
Analysis of Variance , Animals , Carbamazepine/pharmacology , Ethosuximide/pharmacology , Exploratory Behavior/drug effects , Female , Male , Mice , Valproic Acid/pharmacologyABSTRACT
Male Wistar rats were sugjected to daily sessions of electrical amygdala kindling until a generalized seixure was observed on five consecutive days. Bilateral microinections (0.5 micronl) of ethosuximide (ETX) (10 pg/micronl) or saline were then administered though guide cannulas into the substantia nigra (pars reticulata). No significant difference was observed between the ETX (N = 8) and saline (N = 8) groups in duration of afterdischarge or in the latency for stage 5 generalized seizures. Our results indicate that ETX applied to the substantia nigra is not effective in suppressing amydala-kindled seizure
Subject(s)
Rats , Animals , Male , Amygdala/drug effects , Ethosuximide/pharmacology , Kindling, Neurologic/drug effects , Seizures/physiopathology , Substantia Nigra/physiology , Amygdala/physiology , Electric Stimulation , Electroencephalography , Ethosuximide/administration & dosage , Kindling, Neurologic/physiology , Microinjections , Rats, Inbred Strains , Substantia NigraABSTRACT
Se obtuvo la inhibición total del desarrollo fúngico in vitro durante 48 o más horas, al agregar al medio de cultivo los fármacos siguientes: para Acremonium potronii y A. falciforme 50 ug/ml de sulfametoxazol; para Fusarium solanii sulfametoxazol 100 ug/ml más fenilbutazona 30 ug/ml más etosuccimida 100 ug/ml o sulfametoxazol 100 ug/ml mas ibuprofeno 30 ug/ml más etosuccimida 100 ug/ml; para Candida albicans y Aspergillus niger ketoconazol 0.5 ug/ml más gentamicina 3-10 ug/ml; para A. fumigatus sulfametoxazol 100 ug/ml más yoduro de potasio 100 ug/ml más metamizol 100 ug/ml o sulfametoxazol 80-100 ug/ml más fenilbutazona 20-30 ug/ml más etosuccimida 100 ug/ml; o sulfametoxazol 80 ug/ml más clorpromacina 10 ug/ml
Subject(s)
Antifungal Agents/pharmacology , Fungi/drug effects , In Vitro Techniques , Acremonium/drug effects , Aspergillus fumigatus/drug effects , Aspergillus niger/drug effects , Candida albicans/drug effects , Chlorpromazine/pharmacology , Dipyrone/pharmacology , Drug Combinations , Ethosuximide/pharmacology , Fusarium/drug effects , Gentamicins/pharmacology , Ibuprofen/pharmacology , Ketoconazole/pharmacology , Phenylbutazone/pharmacology , Potassium Iodide/pharmacology , Sulfamethoxazole/pharmacologyABSTRACT
Pretreatment with ethosuximide, a drug of choice for petit mal epilepsy, was found to inhibit the conditioned avoidance response in rats and the traction response in mice and to antagonise methamphetamine induced stereotyped behaviour in rats. Our results, which indicate the ethosuximide is capable of inhibiting the dopaminergically mediated behaviours, are in agreement with the recent reports stating that ethosuximide exerts central dopamine receptor blocking activity.